Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’s Vyvgart is already making headway in the rare disease space, just one of the long-term growth ...

This week, we are going to continue down the road of autoimmune peripheral nerve conditions to discuss two that we have touched on in the past—Guillain-Barré Syndrome and CIDP (chronic inflammatory ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) results in disability through immune-mediated nerve injury, which can lead to irreversible deficits after the inflammatory component of CIDP is ...

MONTREAL — An open-label extension study of subcutaneous efgartigimod PH20 to treat chronic inflammatory demyelinating polyneuropathy (CIDP) showed durability of functional improvements to week 24, ...

If you have chronic inflammatory demyelinating polyneuropathy (CIDP), you may have encountered delays and missteps before finally getting diagnosed. Getting the correct diagnosis can be tricky when ...

A blockbuster Argenx therapy now has an additional FDA approval as a treatment for a rare autoimmune disorder affecting nerves, marking the first new treatment for this condition in decades and a new ...

Takeda kicked off 2024 by reeling in an approval for HyQvia in chronic inflammatory demyelinating polyneuropathy (CIDP), and it’s closing out the year by launching its first direct-to-consumer ...

Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of the ...

Get tips to manage health anxiety, loneliness, and other mental health challenges that come with chronic inflammatory demyelinating polyneuropathy.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired neurological disorder with heterogeneous presentation. It is a peripheral nerve system immune-mediated condition which ...